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Purpose: To demonstrate the utility of an amplification-free long-
read sequencing method to characterize the Fuchs endothelial
corneal dystrophy (FECD)-associated intronic TCF4 triplet repeat
(CTG18.1).
Methods: We applied an amplification-free method, utilizing the
CRISPR/Cas9 system, in combination with PacBio single-molecule
real-time (SMRT) long-read sequencing, to study CTG18.1. FECD
patient samples displaying a diverse range of CTG18.1 allele lengths
and zygosity status (n= 11) were analyzed. A robust data analysis
pipeline was developed to effectively filter, align, and interrogate
CTG18.1-specific reads. All results were compared with conven-
tional polymerase chain reaction (PCR)-based fragment analysis.
Results: CRISPR-guided SMRT sequencing of CTG18.1 provided
accurate genotyping information for all samples and phasing was
possible for 18/22 alleles sequenced. Repeat length instability was
observed for all expanded (≥50 repeats) phased CTG18.1 alleles
analyzed. Furthermore, higher levels of repeat instability were
associated with increased CTG18.1 allele length (mode length ≥91
repeats) indicating that expanded alleles behave dynamically.
Conclusion: CRISPR-guided SMRT sequencing of CTG18.1 has
revealed novel insights into CTG18.1 length instability. Further-
more, this study provides a framework to improve the molecular
diagnostic accuracy for CTG18.1-mediated FECD, which we
anticipate will become increasingly important as gene-directed
therapies are developed for this common age-related and sight
threatening disease.
Genetics in Medicine (2019) https://doi.org/10.1038/s41436-019-
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INTRODUCTION
Currently there are more than 40 human diseases that are
caused by the expansions of simple nucleotide repeat
sequences (microsatellites), with diagnosis and prognosis
often dependent on accurate sizing of mutant alleles.1 Despite
the significant advances in sequencing technologies over the
past decade, microsatellites are still typically investigated in a
diagnostic setting using polymerase chain reaction (PCR)-
based amplification methods and fragment sizing by capillary
electrophoresis. When microsatellites expand they become
intractable to standard short-read next-generation sequencing
(NGS) technologies due to their innate repetitive nature, size,
and typically high GC content. Furthermore, when there are
large differences in size between wild-type and mutant
expanded alleles, as is often the case for autosomal dominant
disorders, skewed allelic amplification efficiencies hinder
amplification-based protocols and their analyses.2
Fuchs endothelial corneal dystrophy (FECD; OMIM
613267) affects up to 4.5% of individuals over 50 years of
age.3 Approximately 75% of cases harbor a noncoding CTG
microsatellite expansion termed CTG18.1, making FECD the
most prevalent triplet repeat-mediated disease in humans.4
FECD is an age-related, degenerative condition that primarily
affects the posterior corneal layers and it is the most frequent
indication for corneal transplantation in the developed
world.5 It is clinically characterized by the accelerated loss
of endothelial cells and progressive thickening of Descemet
membrane with focal excrescences termed guttae.6 In
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advanced disease, loss of endothelial cell function leads to
corneal edema, progressive corneal opacity, and reduced
vision.7 Expansion of CTG18.1 situated on Chr18q21.1 within
an intron of TCF4 was first shown to be significantly
associated with FECD in 2012.8 Using a combination of
short tandem repeat (STR) assays and Southern blotting the
authors demonstrated that 79% of the patient cohort had at
least one expanded copy of the triplet CTG motif (defined as
≥50 repeats) compared with 3% of control individuals.8 This
striking association has subsequently been replicated in
ethnically distinct populations using comparable methodolo-
gies.4,8–10 Typically, FECD patients harbor heterozygous
expansions of the repeat in the range of 50–200 repeat units;
however for a few patients, much larger expansions estimated
to be up to several thousand repeat units have been identified
by Southern blotting.8,9,11
In this study we demonstrate a custom application of an
amplification-free long-read sequencing method (BioRxiv:
https://doi.org/10.1101/203919) to specifically study the TCF4
repeat element at a nucleotide level. The method, termed no-
amp targeted sequencing, utilizes the CRISPR-Cas9 system to
target, enrich, and isolate desired DNA fragments in a
non–amplification dependent fashion.12–14 In combination
with long-read single-molecule real-time (SMRT) sequen-
cing15,16 this approach enabled us to analyze the disease-
associated tandem repeat at a nucleotide level within a FECD
patient cohort.
MATERIALS AND METHODS
Selection of FECD patient genomic DNA samples and STR
genotyping assay
This study followed the tenets of the Declaration of Helsinki
and was approved by the Moorfields Eye Hospital (MEH)
ethics committee (09/H0724/25). A diagnosis of FECD was
based on the presence of characteristic confluent corneal
guttae on slit-lamp biomicroscopy, or a previous history of a
corneal transplant for FECD. Written informed consent was
obtained from all participants. Genomic DNA samples were
initially genotyped for CTG18.1 using a short tandem repeat
(STR) assay as described previously.4,8 Throughout this study
expanded CTG18.1 alleles are defined as comprising ≥50 CTG
repeats.
Design of guide RNAs for Cas9 digestion
DNA sequences surrounding the CTG18.1 locus and the
fragile X syndrome–associated CGG triplet repeat located
within FMR1 were used to design Cas9 guide RNAs (gRNAs).
gRNAs were formed by duplexing CRISPR RNA (crRNA)
with trans-activating crRNA (tracrRNA). Candidate target
sequences were generated using an online CRISPR RNA
configurator available on the Dharmacon website, and target
specificity was checked against the human genome reference
sequence (CRISPR Design Tool: https://dharmacon.
horizondiscovery.com/gene-editing/crispr-cas9/crispr-design-
tool/). Final crRNA sequences used for the CRISPR/Cas9
experiment were manually selected to generate a target
capture region of approximately 1 kb from the Cas9 digestion
site to the nearest EcoRI or BamHI digestion site, according to
the hg19 reference. crRNA sequence specificity was verified by
BLAST search against the human genome and the 3’ end of
the crRNA was designed to be oriented toward the region of





Amplification-free Cas9-targeted enrichment of the TCF4
and FMR1 loci
Approximately 5–20 µg of native genomic DNA was frag-
mented with high-fidelity restriction enzymes KpnI and
EcoRV in the presence of calf intestinal alkaline phosphatase
(CIP) (New England Biolabs) to first reduce genome
complexity. Sample DNA was subsequently fragmented with
EcoRI and BamHI (New England Biolabs) and ligated to
restriction site–specific hairpin adapters carrying overhangs
for EcoRI and BamHI cut sites (5’-GATCATCTCTCTCT
TTTCCTCCTCCTCCGTTGTTGTTGTTGAGAGAGAT-3’
and 5’-AATTATCTCTCTCTTTTCCTCCTCCTCCGTTGTT
GTTGTTGAGAGAGAT-3’) to form SMRTbell template
libraries using E. coli DNA ligase (New England Biolabs).
DNA fragments previously cut with the restriction enzymes
KpnI and EcoRV were not compatible with SMRTbell
adapters and were subsequently digested by exonuclease.
Next, 1 µg of SMRTbell template was digested using 32 nM
Cas9 nuclease (New England Biolabs) and 48 nM target
specific gRNAs (Integrated DNA Technologies) in 50 µl
digestion reaction for 1 hour. crRNAs duplexed to tracrRNA
at a 1:1 ratio was used for the Cas9 digestion step. Both TCF4
and FMR1 (positive control) gRNAs were multiplexed in the
same digestion reaction. PolyA hairpin capture adapters (5’-
ATCTCTCTCTTAAAAAAAAAAAAAAAAAAAAAAATT
GAGAGAGAT-3’) were ligated to the DNA molecules
targeted by the Cas9 digestion to form a library of
asymmetrical SMRTbell template molecules.
DNA molecules, with ligated capture adapters, were
enriched using a MagBead system (PacBio). Binding of
capture adapters to a MagBead complex was carried out by
incubating components in MagBead binding buffer for 2
hours at 4 °C. MagBeads with bound target fragments
were then eluted using elution buffer (PacBio) for 10 minutes
at 65 °C.
Targeted SMRT sequencing
Target fragments were prepared for SMRT sequencing by
annealing a standard PacBio primer lacking PolyA sequence
and incubating at room temperature for 1 hour. Then, 0.6×
AMpure Beads were used to remove unbound primer. DNA
molecule/primer complexes were subsequently bound with P6
polymerase in the presence of free hairpin adapters to remove
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excess polymerase. Sequencing was completed using the
PacBio RSII instrument with one-cell-per-well MagBead
sequencing protocol, P6/C4 chemistry, and 240-minute run
time. Circular consensus sequencing (CCS) reads were
generated using PacBio SMRTPortal (version 2.3) software
with a 90% predicted accuracy setting.
Genome-wide coverage plots
Genome-wide coverage plots were generated for each sample
from total CCS reads using PacBio SMRTPortal (version 2.3),
in accordance with methods outlined previously (https://doi.
org/10.1101/203919).
Alignment, filtering, and base calling of locus-specific CCS
reads
On-target CCS reads were identified by mapping the flanking
sequences on either side of the repeat region. Mapped reads
were then further filtered to only retain reads with ≥90%
similarity to the flanking sequences, irrespective of the
CTG18.1 repeat length. On-target CCS read sequences for
each sample were then visualized to identify the biallelic CTC
repeat lengths, and to determine the maximum CTG18.1
repeat length present per sample. Consensus sequence
mapping was also used to identify the genotype of a
polymorphic intronic TCF4 SNP situated downstream of
CTG18.1 (rs599550) for each allele of each sample.
On-target CCS reads were subsequently mapped to a pool
of reference sequences that included allele-specific flanking
sequences (CTC repeat lengths, rs599550 genotype) and CTG
repeat sizes up to the maximum length previously determined
(per sample). Phasing was possible when individuals were
either heterozygous for the single-nucleotide polymorphism
(SNP) (rs599550) or harbored informative heterozygous CTC
repeat lengths. The best matching reference sequence (≥99%
match) for each CCS read was used to infer CTG18.1 repeat
length. Frequency histogram plots were generated, using
phasing information when possible, to show repeat length
reads per sample. For samples that could not be phased, the
modal repeat length per local maxima of mapped reads was
identified. Mapping was completed using Blasr (https://
github.com/PacificBiosciences/blasr).
FMR1 repeat lengths were determined according the
protocol previously described by Hoijer et al.13 using the




Sample selection and amplification-free Cas9-targeted
enrichment
To ascertain whether CRISPR-guided SMRT sequencing
could effectively resolve expanded copies of the CTG18.1
locus, whole blood–derived genomic DNA samples from
FECD patients with a diverse range of CTG18.1 allele lengths
and zygosity status, previously defined by STR genotyping
assay, were selected for analysis.4,8 In total, 11 DNA samples
from the following categories were analyzed: 2 samples with
biallelic nonexpanded (<50 repeats) alleles (category A),
5 samples with presumed monoallelic expansions (≥50
repeats) (category B), and 4 samples with presumed biallelic
expansions (category C; Table 1).
An overview of the amplification-free template preparation
method employed is presented in Fig. 1a. In brief, the patient-
derived DNA samples underwent a series of restriction enzyme
digestion steps to first reduce genome complexity, and then to
introduce adapter-compatible overhangs for SMRTbell library
preparation. Enrichment of the desired loci was achieved by
Cas9-mediated digestions of the SMRTbell libraries using
CTG18.1 (Fig. 1b) and previously optimized FMR1-specific13
gRNAs. Digested templates were enriched by ligation to new
hairpin adapters and purified using MagBeads. For control
purposes we used a multiplexing approach by cotargeting,
enriching, and isolating a fragile X syndrome–associated CGG
triplet repeat located within FMR1, at the same time as the
FECD-associated CTG18.1 locus.
Analysis of SMRT sequencing reads shows expected target
capture
SMRTbell libraries were sequenced using a PacBio RSII
instrument, generating reads of up to 7.1 kb in length.15 Each
CCS read generated comprised multiple passes over a single
DNA molecule due to the circular nature of the SMRTbell
templates being sequenced.17 CCS reads were then mapped
onto the human genome (hg19) and genome-wide coverage
plots were generated (Supplementary Figure S1). Each
sample-specific plot displayed clear peaks representative of
on-target reads mapped to the captured loci on chromosomes
18 (CTG18.1) and X (FMR1). The average number of on-
target CCS reads generated, per sample, was 207 for the FMR1
loci and 897 for the TCF4 loci (Table 1). The FMR1 repeat
region was successfully captured and analysis of the locus, as
anticipated, did not detect any disease-associated repeat
expansions (defined as >55 copies of the CGG repeat18)
within our FECD cohort (Table 1). Off-target reads were
observed for all samples. The most notable and consistent off-
target coverage peak was observed on chromosome 21
(Chr21: 19,639,348-19,639,367). We were able to retrospec-
tively attribute this signal to a region with similarity to the
TCF4-specific gRNA targeted region on Chr18: 53,252,023-
53,252,042. In total, four mismatches were detected between
the TCF4-specific gRNA sequence and the nontargeted region
on chromosome 21 (Supplementary Figure S2). Additionally,
lower levels of off-target reads were found to consistently map
to the centromeric region of chromosome 10: 42,383,760-
42,393,200 (Supplementary Figure S1). However, this signal
was determined to be mapping artifact due to the high levels
of mismatches between the reads and reference genome
(Hg19). All off-target reads generated were filtered as part of
our selection and filtering strategy (see below) and hence did
not affect analysis of TCF4 or FMR1-specific reads.
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Selection and analysis of CTG18.1-derived SMRT
sequencing reads
This is the first time, to the best of our knowledge, that
CRISPR-guided SMRT sequencing has been used to generate
long-read sequencing data for the CTG18.1 locus and we
therefore needed to develop an analysis pipeline to effectively
select and interrogate CTG18.1-specific reads. Firstly, CCS
reads were filtered to exclude those that did not encompass
regions flanking the repeat (Fig. 1c). Next, a preliminary
analysis step was performed to estimate the maximum repeat
lengths, per sample, and to determine if informative
polymorphisms were present within the flanking regions.
Importantly, two commonly polymorphic markers were
identified within flank 2 (Fig. 1b, c): a CTC repeat located
immediately 3’ to the CTG repeat of interest, and a
polymorphic SNP (rs599550) 1320 bp downstream of
CTG18.1. The CTC repeat lengths in our cohort ranged from
8 to 15 copies and always included one CTT repeat
interruption. When individuals were found to be hetero-
zygous for either the length of this repeat or rs599550, we had
the potential to phase reads. Within this cohort we were able
to phase 9/11 samples on this basis (Table 1).
Subsequently, a more comprehensive mapping approach
was employed to accurately determine repeat lengths. This
involved mapping CCS reads to a customized pool of
reference templates, devised after our initial TCF4
loci–specific analysis step, which comprised all possible
combinations of CTG18.1 allele lengths, in addition to the
previously determined polymorphic marker genotypes, when
appropriate (rs599550 and CTC repeat; Fig. 1b and c). Only
reads that achieved ≥99% similarity to a sequence within the
customized pool of templates were included. Sized on-target
reads were then visualized and histograms were generated to
depict the range of CTG18.1 repeat lengths observed in each
sample (Figs. 2 and 3; Supplementary Figure S3).
CRISPR-guided SMRT sequencing of CTG18.1 improves
genotyping accuracy and reveals that expanded CTG18.1
alleles behave dynamically
Given that all samples included in this study had previously
been genotyped for CTG18.1 by STR analysis we were able to
make a direct comparison between the alternative methods.
Average allele lengths observed by CRISPR-guided SMRT
sequencing for samples comprising nonexpanded CTG18.1
alleles (categories A [n= 4 alleles] and B [n= 5 alleles]) were
concordant with our previous STR analysis. However, a
discrepancy of one or more repeat units per allele was noted
between these differing methods. For example, sample 1 had
previously been genotyped 12/15 by STR analysis whereas
CRISPR-guided SMRT sequencing results suggested a geno-
type of 11/14 (Table 1). These differences are likely in part
attributed to variability in the size of the polymorphic CTC
repeat located directly 3’ of CTG18.1, given that the STR assay
cannot distinguish differences in CTG18.1 length from
variability in the length of flanking regions included within
PCR amplimer.4 All sizing estimates calculated by STR
analysis are based upon the reference genome (hg19), which
contains 12 copies of the CTC motif. When this length
deviates from 12 (e.g., sample 1), or indeed if any further
insertions or deletions are present within the PCR amplified
region, it will impede the accuracy of CTG18.1 sizing
estimates provided by the STR assay. Data generated from
category A samples (Supplementary Figure S3: Table 1)
therefore exemplify that CRISPR-guided SMRT sequencing
can effectively sequence biallelic nonexpanded CTG18.1
alleles and, importantly, the sequence level data generated
provides improved levels of genotyping accuracy in compar-
ison with STR analysis.
Importantly, much greater differences were observed
between the STR and CRISPR-guided SMRT sequencing
results for all expanded alleles analyzed (categories B [n= 5
alleles] and C [n= 8 alleles]). This is attributed to the
CTG18.1 instability detected for all expanded CTG18.1 alleles
sequenced using the CRISPR-guided SMRT sequencing
method (samples 3–11; Table 1). The histograms presented
in Figs. 2 and 3 and the dot plot presented in Fig. 4 illustrate
this point. For category B samples, it is apparent that alleles
comprising expanded copies of CTG18.1 (≥50 copies) display
greater levels of mosaicism than nonexpanded alleles (<50
copies) (samples 3–7; Fig. 2). Furthermore, levels of repeat
length instability were found to increase with average allele
length (Fig. 4; Table 1). For example, expanded alleles from
samples 6 and 7 have mean repeat lengths of 171 and 425,
repeat size ranges of 466 and 1244, and maximum repeat
lengths of 566 and 1361, respectively. Whereas, samples 3, 4,
Fig. 1 Schematic of CRISPR-guided single-molecule real-time (SMRT) sequencing methodology, targeted capture design, and downstream
analysis strategy for the CTG18.1 loci. (a) First, genomic DNA underwent a complexity reduction step by digestion with selected restriction enzymes not
predicted to cut inside the target region(s); nontargeted fragments were subsequently degraded by exonuclease. Targeted loci, TCF4 CTG18.1 and FMR1
(positive control), are depicted as pink and yellow respectively. A SMRTbell (green) library was created after target loci were excised by EcoRI and BamHI.
Guide RNAs (gRNAs) targeted specifically to sequence adjacent to the desired regions (TCF4 and FMR1) enabled Cas9 digestion. Cas9-digested SMRTbell
fragments were ligated with engineered capture adapters (purple) and the fragments were attached to MagBeads. (b) EcoRI sites surrounding the CTG18.1
repeat element were identified for target capture. A gRNA Cas9 cut site was selected downstream of the CTG18.1 repeat (pink). Polymorphisms including a
CTC repeat (blue) and single-nucleotide polymorphism (SNP) rs599550 (green/orange) were encompassed within the targeted region. (c) On-target read
selection was performed by filtering reads that did not contain two flanking regions either side of the repeat locus (≥90% mapping required, not including
repeat). Whenever possible CTC repeat length and/or SNP heterozygosity was used to phase circular consensus sequencing (CCS) reads. Once phased, CCS
reads were mapped against a pool of reference sequences of all possible CTG18.1 repeat lengths. The reference sequence with the greatest similarity to
each individual CCS read was used to infer the CTG repeat length.
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and 5 all have comparatively shorter average expanded repeat
lengths (71, 72, and 82), display less diverse repeat size ranges
(25, 66, and 98), and maximum repeat lengths detected, per
sample, are lower (90, 115, and 169) (Table 1; Fig. 2; Fig. 4).
Interestingly, the same pattern is also apparent for the phased
samples 8, 9, and 10; (Fig. 3) where CTG18.1 repeat length
instability positively correlates with the mean CTG18.1 length
(Table 1; Fig. 4).
Importantly, CRISPR-guided SMRT sequencing also
enabled us to comprehensively characterize biallelic expan-
sions of CTG18.1 for the first time. Phased samples 8, 9, and
10 all harbored biallelic expansion with average repeat lengths
of 82/126, 74/272, and 70/175 respectively. Previous STR
analysis of the same samples could only provide sizing
estimates for the smallest alleles present in each sample
(Table 1). Additionally, analysis of phased CCS reads
generated from sample 7 enabled us to identify a GTG repeat
interruption within the nonexpanded allele comprising 17
repeats (Fig. 2, sample 7, inset). Both these examples highlight
the power of the approach and advantages of using CRISPR-
guided SMRT sequencing over STR analysis to genotype
CTG18.1.
400
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Fig. 2 Histograms to illustrate CTG18.1 repeat length distributions for samples harboring monoallelic expansions (category B). Histograms
show CTG18.1 repeat length read counts after filtering circular consensus sequencing (CCS) reads with ≥99% similarity to the best matched reference
sequence. All samples (3–7) could be phased using CTC repeat number and/or rs599550. A single base pair interruption was identified on a single
nonexpanded allele (sample 7) by overlapping and visualizing aligned CCS reads (inset).
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Stringency thresholds for read confidence requires
compromise
Low levels of potentially incorrectly phased CCS reads
were observed using our CCS read selection and analysis
strategy for samples 2, 4, 6, and 9 (Figs. 2 and 3 and
Supplementary Figure S3). To determine if we could
improve phasing confidence, we increased the percentage
similarity filtering threshold used from ≥99% to ≥99.9% and
reanalyzed all samples. As described previously, sized on-
target reads were then visualized and histograms were
generated to depict the range of CTG18.1 repeat lengths
observed in each sample. This more stringent filtering
approach resulted in only one single CCS read containing
an expanded copy CTG18.1 remaining phased, potentially
incorrectly, to an unexpanded allele. This read was generated
from sample 6 and had been phased using the CTC motif only
(Table 1). However, it was noted that using this approach
inappropriately filtered all reads generated from sample 7 that
50
Sample 8 (65 years)
Sample 9 (85 years)
Sample 10 (85 years)













































































































































































































































Fig. 3 Histograms to illustrate CTG18.1 repeat length distributions for samples harboring biallelic expansions (category C). Histograms show
CTG repeat length read counts after filtering circular consensus sequencing (CCS) reads with ≥99% similarity to the best matched reference sequence. All
sequenced alleles display repeat length instability. Samples 8–10 could be phased using CTC repeat number and/or rs599550. Sample 11 was unable to be
phased; however, local maxima were indicative of two alleles being detected and sequenced.
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contain a repeat interruption, due to its absence from the
reference template sequence to which the data is aligned
(Fig. 2), highlighting the limitations of using such a stringent
filtering threshold.
DISCUSSION
Here we demonstrate the utility of CRISPR-guided SMRT
sequencing to interrogate the FECD-associated repeat motif,
CTG18.1. Our proof-of-concept study illustrates that this
amplification-free targeted enrichment approach, used in
combination with long-read SMRT sequencing, can generate
accurate sequencing data for clinically relevant samples.
Furthermore, striking levels of repeat length instability and
mosaicism were observed in our studied patient cohort,
highlighting that size estimates provided by conventional
genotyping assays (e.g., STR and Southern blot) do not
provide a robust representation of the dynamic nature of this
repeat element in its expanded state. Large-scale application
of CTG18.1 locus-specific CRIPSR-guided SMRT sequencing
will have great diagnostic utility and will enhance our
understanding of CTG18.1 genotype diversity within FECD
patient and control populations in addition to furthering our
understanding of phenotype–genotype correlations for this
common age-related disease.
In this study, we achieved an average of 327 reads per
sample and had sufficient coverage to confidently determine
CTG18.1 repeat lengths for all samples analyzed. On-target
read depth was however notably lower for alleles comprising
larger repeats, likely attributed to the inherent size difference
between molecules being sequenced. Furthermore, we were
able to phase reads for 9 of 11 samples analyzed.
Future adaptations of this technology could consider
modifying the size of the targeted flanking regions to
maximize the likelihood of encompassing informative poly-
morphic markers to enhance phasing capabilities. To improve
coverage, future efforts should focus on (1) gRNA design to
reduce off-target Cas9 activity (e.g., off -target effect observed
on Chr21; Supplementary Figures S1 and S2), (2) refinement
of the pull-down stage of the protocol to reduce levels of
SMRTbell molecules not cleaved by Cas9 being pulled down
and sequenced, and (3) updating to the PacBio Sequel System
6.0 to enable increased multiplexing capacity at reduced cost
with lower DNA input requirements. Importantly, reducing
the required DNA input concentration for this method would
also enable future analysis of corneal endothelial cell–derived
DNA, which has the potential to provide insights into the
tissue-specific nature of FECD. Furthermore, increasing
multiplexing capacity will aid the diagnostic utility of the
method. Notably, Tsai and colleagues have demonstrated that
the method is already amenable to multiplexing across
multiple genomic loci (bioRxiv: https://doi.org/10.1101/
203919).
Instability of CTG18.1 repeats appears to consistently occur
for the expanded alleles investigated in this study (n= 13).
Furthermore, greater levels of instability are found with
increased CTG18.1 length (Fig. 4) and were not found to
correlate with donor age (Table 1). This phenomenon has
previously been observed for other repeat expansion-mediated
diseases.13,14,19,20 As anticipated, unexpanded alleles appeared
to be relatively stable (n= 9). Prior to this study, all methods
used to determine CTG18.1 repeat length, including STR
analysis and Southern blotting, only provided crude sizing
estimates and mode allele lengths.8,21 Our study highlights

























1 2 3 4 5 6 7 8 9
Sequenced alleles











Fig. 4 CTG18.1 instability is correlated with repeat length. Dot plot highlights the change in magnitude of repeat instability observed across all phased
alleles (n= 18). Samples are arranged in order of increasing mean allele length (plotted black lines represent mean per allele). Alleles are colored in
accordance to sample numbers (2–10). A dashed line represents the disease-associated threshold of 50 repeats.
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sizing estimates for up to approximately ≤80 copies of the
repeat element, they do not provide an accurate reflection of
the true distribution of allele lengths when larger unstable
expansions are present. This explains the discordant mode
and mean allele lengths observed for alleles comprising ≥91
copies of the repeat (Table 1). It also highlights that we should
move away from considering CTG18.1 genotypes as stable
entities in the expanded state and acknowledge that they are
dynamic units. Future application of this technology has the
potential to characterize the extent of tissue, and age-
dependent mosaicism, that will likely provide both diagnostic
and biological insights into CTG18.1-mediated disease
mechanisms.
In this study we detected a single GTG interruption within
the CTG18.1 motif on a nonexpanded allele (sample 7). This
interruption was readily detectable via visualization of aligned
CCS reads. Intriguingly, up to 4.2% of unaffected aged
populations harbor CTG18.1 expansions but it is not yet
understood why these individuals remain unaffected.4,8
Interruptions of disease-associated repeat expansions have
been shown to modulate phenotypic expressivity by interfer-
ing with DNA and RNA stability and/or downstream gain-of-
function mechanisms.22–25 Future application of this sequen-
cing technology could be used to address the lack of disease
observed in unaffected individuals harboring presumed
CTG18.1 expansions and/or atypical phenotype–genotype
correlations observed within the patient population. However,
the detection of interruptions within large expanded copies of
the repeat motif will likely pose a challenge given the expected
prominent levels of repeat length instability predicted to occur
on such alleles.
There is great clinical need to develop new FECD treatment
strategies.5,6 Corneal transplantation is currently the only
effective treatment option, and this relies upon an adequate
supply of high quality donor material of which there is a
global shortage.5,26 Given that expansion of CTG18.1 is
associated with >75% of FECD cases4,8–10 there is now much
interest in developing gene-directed, CTG18.1-mediated
treatment strategies.4,6,27 CRISPR-guided SMRT sequencing
has the potential to aid the design and implementation of
CTG18.1-targeted therapies in a clinical setting, providing a
diagnostic framework for accurate and high-throughput
CTG18.1 genotyping and informing genotype-dependent
efficacy and outcomes. Given that the disease usually presents
during the fifth to sixth decade of life, CRISPR-guided SMRT
sequencing also has the potential to facilitate presymptomatic
detection and identify patients suitable for future preventive
therapies.
In conclusion, this custom application of CRISPR-guided
SMRT sequencing has provided novel insights into levels
of CTG18.1 length instability within an affected FECD
cohort. Furthermore, this study provides a framework for
improving molecular diagnostic accuracy for FECD, which is
anticipated to become increasingly important as gene-directed
therapies are developed for this common age-related
disease.4,27
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